Complete financial analysis of Zanite Acquisition Corp. (ZNTEU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zanite Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Nordea Bank Abp (NDA-SE.ST) Income Statement Analysis – Financial Results
- South Bow Corporation (SOBO) Income Statement Analysis – Financial Results
- MetaWorks Platforms, Inc. (MWRK.CN) Income Statement Analysis – Financial Results
- Kemira Oyj (KEMIRA.HE) Income Statement Analysis – Financial Results
- GUNANUSA ERAMANDIRI TBK (GUNA.JK) Income Statement Analysis – Financial Results
Zanite Acquisition Corp. (ZNTEU)
About Zanite Acquisition Corp.
Zanite Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the aviation, aerospace and defense, urban mobility, and emerging technology industries. The company was incorporated in 2020 and is based in Cleveland, Ohio.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 6.10M | 353.54K |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 6.10M | 353.54K |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 6.10M | 353.54K |
| Cost & Expenses | 6.10M | 353.54K |
| Interest Income | 23.40K | 0.00 |
| Interest Expense | -20.62M | 0.00 |
| Depreciation & Amortization | 20.62M | 2.67K |
| EBITDA | 14.52M | -350.87K |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -6.10M | -353.54K |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 20.62M | 2.67K |
| Income Before Tax | 14.52M | -350.87K |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | -20.62M | -203.62K |
| Net Income | 35.14M | -350.87K |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | 1.22 | -0.01 |
| EPS Diluted | 1.22 | -0.01 |
| Weighted Avg Shares Out | 28.75M | 28.75M |
| Weighted Avg Shares Out (Dil) | 28.75M | 28.75M |
Zanite Acquisition Corp. Confirms Negotiations with Eve Urban Air Mobility Solutions, Inc.
CLEVELAND--(BUSINESS WIRE)-- #SPAC--Zanite Acquisition Corp. (Nasdaq: ZNTEU) (“Zanite” or the “Company”) today confirmed that it is in negotiations relating to a potential business combination with Eve Urban Air Mobility Solutions, Inc., a subsidiary of Embraer S.A., a Brazilian corporation. There...
Zanite Acquisition Corp. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
CLEVELAND--(BUSINESS WIRE)-- #Ricci--Zanite Acquisition Corp. (Nasdaq: ZNTEU) (the “Company”) today announced that it received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule...
Zanite Acquisition Corp. Announces Sponsor's Intention to Purchase Private Placement Warrants to Extend Completion Window to November 19, 2021
CLEVELAND--(BUSINESS WIRE)-- #SPAC--Zanite Acquisition Corp. (Nasdaq: ZNTEU) (the “Company”) announced today that it has received notice from Zanite Sponsor LLC (the “Sponsor”) of its intention to purchase an additional 2,300,000 private placement warrants (the “Private Placement Warrants”) to extend the...
Zanite Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about January 7, 2021
CLEVELAND--(BUSINESS WIRE)-- #KennRicci--Zanite Acquisition Corp. (Nasdaq: ZNTEU) (the “Company”) announced today that holders of the units sold in the Company's initial public offering of 23,000,000 units completed on November 19, 2020 may elect to separately trade the shares of Class...
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals, which soared 158% on its first day. New filings continued to pour in,...
Source: https://incomestatements.info
Category: Stock Reports